Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer

被引:29
作者
Hamaguchi, Reo [1 ]
Narui, Ryoko [1 ]
Wada, Hiromi [1 ,2 ]
机构
[1] Japanese Soc Inflammat & Metab Canc, Kyoto, Japan
[2] Kyoto Univ, Karasuma Wada Clin, Kyoto, Japan
关键词
Pancreatic cancer; alkalization therapy; tumor microenvironment; alkaline diet; bicarbonate; urine pH; NAIVE JAPANESE PATIENTS; TUMOR ACIDITY; CELLULAR ADAPTATION; P-GLYCOPROTEIN; GEMCITABINE; FOLFIRINOX; EFFICACY; BUFFER; CELLS; LOAD;
D O I
10.21873/anticanres.14020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: The acidic tumor microenvironment is associated both with the progression and drug resistance of cancer. We aimed to investigate the effects of alkalization therapy performed concurrently with chemotherapy on the survival of advanced pancreatic cancer patients (study registration: UMIN 000035659). Patients and Methods: Twenty-eight patients with metastatic or recurrent pancreatic cancer were assessed in this study. Alkalization therapy consisted of an alkaline diet with supplementary oral sodium bicarbonate (3.0-5.0 g/day). Results: The mean urine pH was significantly higher after the alkalization therapy (6.85 +/- 0.74 vs. 6.39 +/- 0.92; p<0.05). The median overall survival from the start of alkalization therapy of the patients with high urine pH (>7.0) was significantly longer than those with low urine pH (<= 7.0) (16.1 vs. 4.7 months; p<0.05). Conclusion: An alkalization therapy may be associated with better outcomes in advanced pancreatic cancer patients treated with chemotherapy.
引用
收藏
页码:873 / 880
页数:8
相关论文
共 32 条
  • [1] Ana Maria Lopez I.F.R., 2014, J. Integr. Oncol, V4, P10, DOI DOI 10.4172/2329-6771.1000128
  • [2] Arunkumar P. A., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P640, DOI 10.1016/S2221-1691(12)60112-9
  • [3] Regulation of cancer cell metabolism
    Cairns, Rob A.
    Harris, Isaac S.
    Mak, Tak W.
    [J]. NATURE REVIEWS CANCER, 2011, 11 (02) : 85 - 95
  • [4] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [5] Why do cancers have high aerobic glycolysis?
    Gatenby, RA
    Gillies, RJ
    [J]. NATURE REVIEWS CANCER, 2004, 4 (11) : 891 - 899
  • [6] Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
    Gerweck, LE
    Vijayappa, S
    Kozin, S
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) : 1275 - 1279
  • [7] Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC
    Hamaguchi, Reo
    Okamoto, Toshihiro
    Sato, Masaaki
    Hasegawa, Michiko
    Wada, Hiromi
    [J]. ANTICANCER RESEARCH, 2017, 37 (09) : 5141 - 5145
  • [8] The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer.: Two faces of the same coin-one single nature
    Harguindey, S
    Orive, G
    Pedraz, JL
    Paradiso, A
    Reshkin, SJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2005, 1756 (01): : 1 - 24
  • [9] Genetics and biology of pancreatic ductal adenocarcinoma
    Hezel, Aram F.
    Kimmelman, Alec C.
    Stanger, Ben Z.
    Bardeesy, Nabeel
    DePinho, Ronald A.
    [J]. GENES & DEVELOPMENT, 2006, 20 (10) : 1218 - 1249
  • [10] Tris-base buffer: a promising new inhibitor for cancer progression and metastasis
    Ibrahim-Hashim, Arig
    Abrahams, Dominique
    Enriquez-Navas, Pedro M.
    Luddy, Kim
    Gatenby, Robert A.
    Gillies, Robert J.
    [J]. CANCER MEDICINE, 2017, 6 (07): : 1720 - 1729